<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<!-- Brand and toggle get grouped for better mobile display -->
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<!-- Collect the nav links, forms, and other content for toggling -->
						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li class="active"><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div><!-- /.navbar-collapse -->
					  </div><!-- /.container-fluid -->
					</nav>
					</div>
				</div><!--Fin de row -->

			</div><!--Fin de container -->

		</div>
	</header> <!--Fin de header -->



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>Toxicities</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section><!-- Fin de Banner Section -->




	<section class="franja">
	 <div class="overlay_franja">
		 <div class="container">
			 <div class="row">
				 <div class="col-md-12 col-sm-12 col-xs-12">
					 <div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
						 <h2>3<span class="negrita">.4</span> LIVER TOXICITY</h2>
						 <br/> <img src="images/ORGANOliverSM.png" alt="" height="50px"/>

					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
 </section>
 <section class="texto">
	 <div class="container">
		 <div class="row">
			 <div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				 <p></p>
			 </div>
		 </div>
	 </div>
 </section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CLINICAL CASE</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Patient diagnosed with stage IIIA T3N0M0 non-small cell lung cancer (NSCLC)</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> In July 2015: Palliative RT on perihilar lesion with PR (concomitant use was ruled out due to PS2).</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Locoregional progression Sept 2016: CBDCA+Paclitaxel with EE</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Locoregional progression in March 2017: (PD-L1 weak positive): Nivolumab with RP </p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Currently undergoing treatment with Nivolumab 3 mg/kg IV every 14 days</p>
							<br/> <br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/>
							<p><span class="negrita">Week 7 treatment:</span></p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Elevated AST/ALT 1.5 times the upper limit of normal (ULN), bilirubin normal</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Asymptomatic patient</p>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="tabla">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

							<h2>Liver toxicity in immunotherapy? </h2>
							<br/> <br/>
							<p>Liver toxicity is a relatively rare adverse effect associated with immunotherapy.</p>
							<br/>
							<p>Less than 1% of these patients develop severe toxicity (GRADE 3-4), except for those who receive the combination of an anti-CTLA4 and an anti-PD1. (Weber, Clin. Cancer Res 2009, Garon N. Engl. J. Med. 2015, Rizvi Lancet Oncol. 2015, Robert, N. Engl. J. Med. 2015 Seiwert, Lancet Oncol. 2016).</p>
							<br/>
							<table class="vikhi-tabla">
							<tr>
								<th><p>Type of checkpoint inhibitor</p></th>
								<th><p>Hepatotoxicity</p></th>
								<th><p>Severe liver toxicity</p></th>
							</tr>
							<tr>
								<td><p>Ipilimumab</p></td>
								<td><p>2%</p></td>
								<td><p>&lt;1%</p></td>
							</tr>
							<tr>
								<td><p>Pembrolizumab</p></td>
								<td><p>2-10%</p></td>
								<td><p>&lt;1%</p></td>
							</tr>
							<tr>
								<td><p>Nivolumab</p></td>
								<td><p>2-5%</p></td>
								<td><p>1%</p></td>
							</tr>
							<tr>
								<td><p>Nivolumab + Ipilimumab</p></td>
								<td><p>22%</p></td>
								<td><p>14%</p></td>
							</tr>
							</table>
							<br/>
							<p>It is usually asymptomatic and is not associated with elevated bilirubin levels, but occasionally fever, malaise or even jaundice and pruritus occur in cases with hyperbilirubinaemia.</p>
							<br/>
							<p>It usually occurs between the 6-12 weeks after starting treatment.</p>
							<br/>
							<p>As previously mentioned, it is important to monitor liver function before each administration of treatment in order to be able to detect early.</p>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>



	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
				<div class="main_counter_content text-center">
				<div class="col-md-12 col-sm-12 col-xs-12">




					<div class="marcoOSCURO wow fadeIn">

					<form>
					<br/> <br/> <br/>
					<h2>Given the possibility of GRADE 1 liver toxicity to Nivolumab, which approach do you think is the most correct?</h2>
					<br/> <br/> <br/> <br/>
					<label class="container">I would stop the Nivolumab and perform tests.
						<input type="radio" name="pregunta1" id="p2">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would initiate corticosteroid therapy without stopping the Nivolumab and perform tests.
						<input type="radio" name="pregunta1" id="p3">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">It is a GRADE 1 toxicity, so I would continue with Nivolumab and perform tests
						<input type="radio" name="pregunta1" id="p4">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would rule out other causes of impaired liver function and would strictly monitor it without stopping the Nivolumab.
						<input type="radio" name="pregunta1" id="p1">
						<span class="checkmark"></span>
					</label>
					</form>


					<div class="pregunta wow fadeIn" data-wow-duration="1s">
						<a href="#"><img onclick="resultado();return false;" src="images/profesora.png" alt="" height="90px"/></a>
					</div>


						<div id="flotante" style="display:none;">


							<br/><br/><h2>Correct!</h2>
							<br/>
							<h2>The correct therapeutic decision would be<span class="negrita">:</span></h2>
							<br/> <br/>
							<p><span class="negrita">•</span> We rule out active alcoholism and other concomitant medications.</p>
							<br/><p><span class="negrita">•</span> We continue Nivolumab and request new tests.</p>
							<div class="separator"></div>

							<p>If impaired liver function is present in a patient receiving immunotherapy, we must always consider this possibility, but we should not forget that we must make a differential diagnosis with other pathologies. <span class="cursiva">(Champat Ann Oncol 2016)</span>.</p>



						</div>
						<div id="flotanteIncorrecto" style="display:none;">
							<br/><br/>
							<h2>This is not correct. Try again :)</h2>

						</div>


					</div>




			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>How do we define liver toxicity?</h2>
					<br/>
					<p>The grades of renal toxicity are defined according to the <span class="cursiva">Common Terminology Criteria for Adverse Events</span> (CTCAE), <span class="cursiva">Version 4.0</span> (CTCAE v4)</p>
					<br/>
					<table class="vikhi-tabla">
					<tr>
						<td><p>GRADE 1</p></td>
						<td><p>Absence of symptoms</p><p>AST or ALT &lt;3 x ULN</p><p>Bi &lt;1.5 x ULN</p></td>
					</tr>
					<tr>
						<td width="15%"><p>GRADE 2</p></td>
						<td><p>AST or ALT &gt;3 and &lt;5 x ULN</p><p>Bi &gt;1.5 and &lt;3 x ULN</p></td>
					</tr>
					<tr>
						<td width="15%"><p>GRADE 3</p></td>
						<td><p>AST or ALT &gt;5 and &lt;20 x ULN</p><p>Bi &gt;3 and &lt;10 x ULN</p></td>
					</tr>
					<tr>
						<td width="15%"><p>GRADE 4</p></td>
						<td><p>AST or ALT &gt; 20 x ULN</p><p>Bi &gt;10 x ULN</p></td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<div class="marcoOSCURO wow fadeIn">

							<form>
							<br/><br/><br/>
							<p>The patient attended the 5th administration of Nivolumab and provided a blood test with AST and ALT 4 times the upper limit of normal and bilirubin 1.7 times the upper limit of normal.</p>
							<br/>
							<h2>What do we do at this point?</h2>

							</form>


							<div class="pregunta wow fadeIn" data-wow-duration="1s">
								<a href="#"><img onclick="mostrarB();return false;" src="images/interrogacion.png" alt="" height="40px"/></a>
							</div>







								<div id="flotanteB" style="display:none;">
									<br/><br/> <br/> <br/>
									<h2>The correct therapeutic decision would be<span class="negrita">:</span></h2>
									<br/> <br/>
									<p><span class="negrita">•</span> Given the suspicion of GRADE 2 liver toxicity, we decided not to administer the planned dose of Nivolumab. We initiated prednisone 30 mg/12 hours and we requested new tests with viral serologies and an abdominal ultrasound.</p>
									<br/><p><span class="negrita">•</span> The serology tests were negative and the liver ultrasound only detected a mild steatosis.</p>
									<br/><p><span class="negrita">•</span> We performed daily controls and liver function progressively improved until normalisation of bilirubin and transaminase to 1.5 times the upper limit of normal after 7 days. For this reason, we restarted Nivolumab and progressively decreased the dose of prednisone until its withdrawal at 5 weeks of treatment (30 mg/12 hours, 1 week- 30 mg/24 hours, 10 days - 15 mg/24 hours, 10 days-10 mg/24 hours, 10 days and withdrawal).</p>
									<br/><p><span class="negrita">•</span> Liver function remains stable and the patient still continues with Nivolumab, maintaining a stabilised partial response.</p>
									<br/>



					 </div>
					</div>





						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>Management of liver toxicity</h2>
					<br/>
					<p>The management of liver toxicity due to immunotherapy will depend on the its level of severity (Kumar Front Pharmacol 2017). We summarise it in the following table:</p>
					<br/>
					<table class="vikhi-tabla">
					<tr>
						<th width="5%"><p>GRADE</p></th>
						<th><p>Management</p></th>
						<th><p>Follow-up</p></th>
					</tr>
					<tr>
						<td width="5%"><p>1</p></td>
						<td width="40%"><p><span class="negrita">•</span> If there are no symptoms, continue immunotherapy</p><p><span class="negrita">•</span> Periodic monitoring of liver function until it is resolved.</p></td>
						<td width="55%"><p><span class="negrita">•</span> If liver function worsens or symptoms appear, treat according to the corresponding degree</p></td>
					</tr>
					<tr>
						<td width="5%"><p>2</p></td>
						<td width="40%"><p><span class="negrita">•</span> Do not administer immunotherapy</p><p><span class="negrita">•</span> Oral prednisone 1 mg/kg/day or equivalent</p><p><span class="negrita">•</span> Daily monitoring of liver function</p></td>
						<td width="55%"><p><span class="negrita">•</span> If the symptoms are resolved and the toxicity decreases to &lt;GRADE 1, restart immunotherapy at the next dose</p>
							<p><span class="negrita">•</span> Descending corticosteroid regimen for at least one month with weekly monitoring of liver function</p><p><span class="negrita">•</span> If there is no response within 3-7 days, consider adding an immunosuppressant (Mycophenolate 500-1000 mg every 12 hours, Tacrolimus, cyclophosphamide)</p>
						  <p><span class="negrita">•</span> Infliximab is contraindicated due to its liver toxicity.</p>
						</td>
					</tr>
					<tr>
						<td width="5%"><p>3-4</p></td>
						<td width="40%"><p><span class="negrita">•</span> Discontinue immunotherapy permanently</p><p><span class="negrita">•</span> IV Methylprednisolone 2-4 mg/kg/day or equivalent</p><p><span class="negrita">•</span> Daily monitoring of liver function</p>
						<p><span class="negrita">•</span> Consider ultrasound and/or biopsy</p></td>
						<td width="55%">
							<p><span class="negrita">•</span> After the symptoms have disappeared and the impaired liver function has been resolved, perform a descending corticosteroid regimen for at least 1 month with weekly monitoring of liver function</p>
							<p><span class="negrita">•</span> If there is no response within 3-7 days, consider adding an immunosuppressant (Mycophenolate 500-1000 mg every 12 hours, Tacrolimus, cyclophosphamide)</p>
							<p><span class="negrita">•</span> Infliximab is contraindicated due to its liver toxicity.</p>
						</td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>
	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<div class="contorno wow fadeIn">
								<h2>Was poor evolution a possibility? What should be done in that case?</h2>
								<br/>
								<p>We have already explained above that GRADE 3-4 liver toxicity due to immunotherapy is extremely uncommon. Despite this, it is an entity that exists, and there has even been a case of fulminant liver failure. (Sarkissian, Austin Oncol, 2016).</p>
								<br/>
								<p>Therapeutic management in this situation has already been described, but it also highlights the contraindication of Infliximab in persistent cases due to its liver toxicity and the indication of Mycophenolate, Tacrolimus or Cyclophosphamide.</p>
								<br/>
								<p>When serious toxicity is suspected, we should always consider a consultation with a hepatology specialist and a liver biopsy should be considered.</p>

						</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>





	<section>
	 <div class="container">
		 <div class="row">

			 <div class="wedo_content_area">

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad01.html"><h4 class="gris">3.1 GASTROINTESTINAL TOX.</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad02.html"><h4 class="gris">3.2 PULMONARY TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad03.html"><h4 class="gris">3.3 RENAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad04.html"><h4 class="gris">3.4 LIVER TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad05.html"><h4>3<span class="turquesa">.5</span> ENDOCRINE TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad06.html"><h4>3<span class="turquesa">.6</span> CUTANEOUS TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad07.html"><h4>3<span class="turquesa">.7</span> NEUROLOGICAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad08.html"><h4>3<span class="turquesa">.8</span> OTHER TOXICITIES</h4></a>
						 </div>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>

	<script type="text/javascript" src="js/test.js"></script>




	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
